You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

83 search results for: mechanism of disease

ADVENT On Air | Exploring PN as a Distinct and Unique <b>Disease</b>

Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

20 min

Dermatology

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.

<b>Disease</b>-Specific Aspects <b>of</b> Itch in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Atopic Dermatitis and Prurigo Nodularis: Distinct skin <b>disease</b>s with shared characteristics

Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

5 min

Dermatology

An infographic exploring the shared and distinct clinical characteristics of atopic dermatitis and prurigo nodularis.

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics

interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

5 min

Dermatology

Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.

expert video

Describing Disease Control in PN

5 min

Dermatology

Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic <b>Disease</b>s and Psychiatric Conditions

expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

2 min

Dermatology

Dr. Sarina Elmariah discusses PN being a unique clinical entity, distinct from other pruritic diseases and psychiatric conditions.

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

The Potential Impact <b>of</b> Early Intervention in Atopic Dermatitis in Children

expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

2 min

Dermatology

Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.

Can advanced systemic therapies modify patho<b>mechanism</b>s in AD?

expert video

Can advanced systemic therapies modify pathomechanisms in AD?

5 min

Dermatology

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

Emerging Understanding <b>of</b> Chronic Itchy Skin <b>Disease</b>s – Shared and Unique Drivers in AD, PN, and CSU

Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

5 min

Dermatology

An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin <b>disease</b> (AD, PN, CSU)?

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

Type 2 Inflammation Alters the Structure and Function <b>of</b> the Skin in Atopic Dermatitis Interview

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

5 min

Dermatology

Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FranceChange country/region